

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-15. (Canceled)

16. (Currently Amended) A method of reducing the incidence of pregnancy in a female subject comprising administering to a female subject an amount of an agent effective at reducing the incidence of conception, wherein the agent comprises a peptide selected from the group consisting of:

- a) a peptide consisting of the LHR^{exo1}, LHR^{exo2} or LHR^{exo3} domain, or any combination thereof;
- b) a peptide about 24-32 residues in length and comprising the amino acid sequence of the LHR^{exo1} domain or a sequence at least 95% identical to the amino acid sequence of the LHR^{exo1} domain;
- c) a peptide about 21-29 residues in length and comprising the amino acid sequence of the LHR^{exo2} domain or a sequence at least 95% identical to the amino acid sequence of the LHR^{exo2} domain; and
- d) a peptide about 12-20 residues in length and comprising the amino acid sequence of the LHR^{exo3} domain or a sequence at least 95% identical to the amino acid sequence of the LHR^{exo3} domain.

wherein the ~~agent~~ peptide binds CG and inhibits CG activity or CG interaction with the exoloop 1, exoloop 2 or exoloop 3 domain of the LHR.

Claim 17. (Canceled)

Claim 18. (Canceled)

Claims 19-53. (Canceled)

54. (New) The method of claim 16, wherein the CG is hCG.

55. (New) The method of claim 16, wherein the female subject is a canine, a feline, an ovine, a primate, an equine, a porcine, a caprine, a camelid, an avian, a bovine, an amphibian, a fish, or a murine subject.

56. (New) The method of claim 16, wherein the sequence is at least 97% identical to the amino acid sequence of the LHR^{exo1}, LHR^{exo2}, or LHR^{exo3} domain.